The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024)

Czech version

Authors: J. Novotný ^1,2; D. Cibula ³; V. Curtisová ⁴; O. Dubová ⁵; L. Foretová ⁶; A. Germanová ³; M. Janatová ⁷; O. Havránek ²; M. Hojsáková ⁸; M. Hudcová ⁹; M. Koudová ¹⁰; V. Krutílková ¹¹; M. Palacova ¹²; S. Paulich ¹³; K. Petrakova ¹²; J. Presl ¹⁴; A. Puchmajerová ⁹; J. Soukupová ⁷; M. Šenkeříková ^15,16; Z. Šimková ¹⁷; H. Štěpánková ¹⁷; I. Šubrt ¹⁸; I. Tachecí ¹⁹; P. Tesner ²⁰; O. Urban ²¹; K. Veselá ²; Š. Vilímová ²²; Z. Vlčková ²³; M. Vočka ^2,24; V. Weinberger ²⁵; M. Zikán ⁵; M. Zimovjanová ²⁴; Z. Kleibl ⁷; P. Kleiblová ^2,7
Authors‘ workplace: Klinická onkologie, Institut klinické a experimentální medicíny, Praha ¹; Ústav bio logie a lékařské genetiky, 1. LF UK a VFN v Praze ²; Klinika gynekologie, porodnictví a neonatologie 1. LF UK a VFN v Praze ³; Ústav lékařské genetiky, FN Olomouc ⁴; Gynekologicko-porodnická klinika 1. LF UK a FN Bulovka, Praha ⁵; Oddělení epidemiologie a genetiky nádorů (člen ERN Genturis), MOÚ, Brno ⁶; Ústav lékařské bio chemie a laboratorní dia gnostiky, 1. LF UK a VFN v Praze ⁷; Oddělení lékařské genetiky, KN Liberec ⁸; Onkologická klinika LF UP a FN Olomouc ⁹; Centrum lékařské genetiky a reprodukční medicíny, Gennet, Praha ¹⁰; Oddělení lékařské genetiky, Laboratoře AGEL a. s., Nový Jičín ¹¹; Klinika komplexní onkologické péče LF MU a MOÚ, Brno ¹²; Oddělení klinické onkologie, KN Liberec ¹³; Gynekologicko-porodnická klinika LF v Plzni UK a FN Plzeň ¹⁴; Oddělení lékařské genetiky, FN Hradec Králové ¹⁵; Lékařská genetika, Prenet, Pardubice ¹⁶; Ambulance lékařské genetiky, Nemocnice České Budějovice ¹⁷; Ústav lékařské genetiky, LF v Plzni UK a FN Plzeň ¹⁸; II. interní gastroenterologická klinika LF v Hradci Králové UK a FN Hradec Králové ¹⁹; Ústav bio logie a lékařské genetiky (člen ERN Genturis), 2. LF UK a FN Motol, Praha ²⁰; II. interní klinika – gastroenterologická a geriatrická LF UP a FN Olomouc ²¹; Oddělení lékařské genetiky, Pronatal, Praha ²²; Oddělení klinické genetiky, GHC Genetics, Praha ²³; Onkologická klinika 1. LF UK a VFN v Praze ²⁴; Gynekologicko-porodnická klinika LF MU a FN Brno ²⁵
Published in: Klin Onkol 2024; 38(5): 384-389
Category: Short Communication
doi: https://doi.org/10.48095/ccko2024384

Overview

The guidelines for clinical practice for carriers of pathogenic variants in clinically relevant genes predisposing to Lynch syndrome and colorectal cancer define the steps of primary and secondary prevention that should be provided to the individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society, in cooperation with representatives of oncology, oncogynecology, and gastroenterology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.

Keywords:

consensus – MLH1 – MSH6 – PMS2 – guidelines for clinical practice – germline mutation carriers – MSH2/EPCAM

Sources

1. ÚZIS. Zdravotnická ročenka České republiky 2021. [online]. Dostupné z: https: //www.uzis.cz/res/f/008435/zdrroccz2021.pdf.

2. Novotný J, Vítek P, Kleibl Z et al. Onkologie v klinické praxi. Praha: Mladá fronta 2019.

3. Moreira L, Balaquer F, Lindor N et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012; 308 (15): 1555–1556. doi: 10.1001/jama.2012.13088.

4. Foretová L, Navrátilová M, Svoboda M et al. Recommendations for preventive care for women with rare genetic cause of breast and ovarian cancer. Klin Onkol 2019; 32 (Suppl 2): 6–13. doi: 10.14735/amko2019S6.

5. Foretová L, Macháčková E, Gaillyová R et al. Hereditární nádorová onemocnění v klinické praxi. Praha: Grada 2022.

6. NCCN. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 3.2024. [online]. Dostupné z: https: //www.nccn.org/guidelines/guidelines-detail?category=2&id=1503.

7. Stjepanovic N, Moreira L, Carneiro F et al. Hereditary gastrointestinal cancers: ESMO clinical practice guidelins for diagnosis, treatment and follow-up. Ann Oncol 2019; 30 (10): 1558–1571. doi: 10.1093/annonc/mdz233.

8. Peltomaki P, Nystrom M, Mecklin JP et al. Lynch syndrome genetics and clinical implications. Gastroenterology 2023; 164 (5): 783–799. doi: 10.1053/j.gastro.2022.08.058.

9. Ercan AB, Aronson M, Fernandez NR et al. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. Lancet Oncol 2024; 25 (5): 668–682. doi: 10.1016/S1470-2045 (24) 00026-3.

10. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809): 2081–2087. doi: 10.1016/S0140-6736 (11) 61049-0.

11. Stjepanovic N, Moreira L, Carneiro F et al. Hereditary gastrointestinal cancers: ESMO clinical practice guidelins for diagnosis, treatment and follow-up. Annals of Oncol 2019; 30 (10): 1558–1571. doi: 10.1093/annonc/mdz 233.

12. Pracovní skupina Společnosti lékařské genetiky (SLG). Doporučení. [online]. Distupné z: https: //www.onkogenetika.cz/doporuceni.html.

13. Česká onkologická společnost ČLS JEP. Lékař a multidisciplinární tým. [online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/.

14. Peltomaki P, Nystrom M, Mecklin JP et al. Lynch syndrome genetics and clinical implications. Gastroenterology 2023; 164 (5): 783–799. doi: 10.1053/j.gastro.2022.08.058.

15. Bonadona V, Bonaiti B, Olschwang S et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305 (22): 2304–2310. doi: 10.1001/jama.2011.743.

16. Moller P, Seppala T, Bernstein I et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017; 66 (3): 464–472. doi: 10.1136/gutjnl-2015-309675.

17. Moller P, Seppala TT, Bernstein I et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018; 67 (7): 1306–1316. doi: 10.1136/gutjnl-2017-314057.

18. Ryan NAJ, Morris J, Green K et al. Association of mismatch repair mutation with age at cancer onset in lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 2017; 3 (12): 1702–1706. doi: 10.1001/jamaoncol.2017.0619.

19. Engel C, Loeffler M, Steinke V et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30 (55): 4409–4415. doi: 10.1200/JCO.2012.43.2278.

20. Dominguez-Valentin M, Joost P, Therkildsen C et al. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol 2016; 16: 15. doi: 10.1186/s12894-016-0130-1.

21. Joost P, Therkildsen C, Dominguez-Valentin M et al. Urinary tract cancer in lynch syndrome; increased risk in carriers of MSH2 mutations. Urology 2015; 86 (6): 1212–1217. doi: 10.1016/j.urology.2015.08.018.

22. Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010; 138 (2): 487–492. doi: 10.1053/j.gastro.2009.10.051.

23. Ercan AB, Aronson M, Fernandez NR et al. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. Lancet Oncol 2024; 25 (5): 668–682. doi: 10.1016/S1470-2045 (24) 00026-3.

24. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809): 2081–2087. doi: 10.1016/S0140-6736 (11) 61049-0.

25. Sessa C, Balmana J, Bober SL et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (1): 33– 47. doi: 10.1016/ j. annonc.2022.10.004.